Despite the risks some healthcare penny stocks have profitable operations
SmallCapPower | July 27, 2016: The Bloomberg Pharmaceuticals, Biotechnology & Life Sciences index has surged 9.32% in the last month, however is still down 1% year-to-date. Healthcare continues to be an unloved investment space for most, and during times of added volatility is often dumped. For those contrarian investors out there, here are five healthcare penny stocks that have positive operating income.
Knight Therapeutics Inc. (TSE:GUD) – $8.49
Pharmaceuticals
Knight Therapeutics Inc. is a specialty pharmaceutical company. Its principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. The Company finances other life sciences companies in Canada and internationally with the goal of earning interest income and securing product distribution rights for Canada and select international markets.
- Market Cap: 1,166,332,240
- Revenues: 1,857,670
- Operating Income: 26,023,430
- Debt to Equity: 0%
Biosyent Inc. (CVE:RX) – $8.85
Pharmaceuticals
BioSyent Inc. is a specialty pharmaceutical company that, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
- Market Cap: 125,329,060
- Revenues: 15,854,560
- Operating Income: 5,027,890
- Debt to Equity: 0%
Nobilis Health Corp. (TSE:NHC) – $3.38
Healthcare Facilities & Services
Nobilis Health Corp. (Nobilis) owns and manages healthcare facilities in the States of Texas and Arizona, consisting primarily of ambulatory surgery centers (ASCs) and acute-care and surgical hospitals. The Company’s segments include Medical Services, Marketing Services and Corporate.
- Market Cap: 215,285,203.21
- Revenues: 322,152,307
- Operating Income: 27,675,385
- Debt to Equity: 33%
Intelgenx Technologies Corp. (CVE:IGX) – $0.69
Pharmaceuticals
IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral immediate-release and controlled-release products. The Company also focuses on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology.
- Market Cap: 114,570,744.63
- Revenues: 7,045,318
- Operating Income: 943,230
- Debt to Equity: 46%
Ceapro Inc. (CVE:CZO) – $2.40
Biotechnology & Medical Research
Ceapro Inc. is a Canada-based growth-stage biotechnology company. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.
- Market Cap: 152,424,669
- Revenues: 13,016,540
- Operating Income: 5,362,220
- Debt to Equity: 46%
DISCLAIMER The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
